383 related articles for article (PubMed ID: 38255905)
1. Modulation of Tau Pathology in Alzheimer's Disease by Dietary Bioactive Compounds.
Shi H; Zhao Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255905
[TBL] [Abstract][Full Text] [Related]
2. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
3. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
4. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
5. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
6. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
[TBL] [Abstract][Full Text] [Related]
7. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
8. SUMO and Alzheimer's disease.
Lee L; Sakurai M; Matsuzaki S; Arancio O; Fraser P
Neuromolecular Med; 2013 Dec; 15(4):720-36. PubMed ID: 23979993
[TBL] [Abstract][Full Text] [Related]
9. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
12. Degradation or aggregation: the ramifications of post-translational modifications on tau.
Park S; Lee JH; Jeon JH; Lee MJ
BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
14. The Role of Copper in Tau-Related Pathology in Alzheimer's Disease.
Zubčić K; Hof PR; Šimić G; Jazvinšćak Jembrek M
Front Mol Neurosci; 2020; 13():572308. PubMed ID: 33071757
[TBL] [Abstract][Full Text] [Related]
15. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
[TBL] [Abstract][Full Text] [Related]
16. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
18. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
19. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
Iqbal K; Alonso AC; Gong CX; Khatoon S; Pei JJ; Wang JZ; Grundke-Iqbal I
J Neural Transm Suppl; 1998; 53():169-80. PubMed ID: 9700655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]